

Robert A S AriÃ«ns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5415821/publications.pdf>

Version: 2024-02-01

144
papers

7,830
citations

34076

52
h-index

56687

83
g-index

146
all docs

146
docs citations

146
times ranked

6600
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrin Clot Structure and Function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, e88-99.	1.1	422
2	Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. <i>Blood</i> , 2002, 100, 743-754.	0.6	322
3	The genetics of haemostasis: a twin study. <i>Lancet, The</i> , 2001, 357, 101-105.	6.3	266
4	Tissue-factor antigen and activity in human coronary atherosclerotic plaques. <i>Lancet, The</i> , 1997, 349, 769-771.	6.3	236
5	Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. <i>Lancet, The</i> , 2003, 361, 1424-1431.	6.3	187
6	Thrombus Composition and Efficacy of Thrombolysis and Thrombectomy in Acute Ischemic Stroke. <i>Stroke</i> , 2021, 52, 1131-1142.	1.0	185
7	The influence of type 2 diabetes on fibrin structure and function. <i>Diabetologia</i> , 2005, 48, 1198-1206.	2.9	181
8	Altered Fibrin Clot Structure in the Healthy Relatives of Patients With Premature Coronary Artery Disease. <i>Circulation</i> , 2002, 106, 1938-1942.	1.6	172
9	Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. <i>Diabetologia</i> , 2006, 49, 1071-1080.	2.9	163
10	Diagnosis and classification of factor XIII deficiencies. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1404-1406.	1.9	157
11	Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. <i>Blood</i> , 2010, 115, 3980-3988.	0.6	143
12	Genetic and Environmental Determinants of Fibrin Structure and Function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1558-1566.	1.1	137
13	Atomic Force Microscopy-Based Molecular Recognition of a Fibrinogen Receptor on Human Erythrocytes. <i>ACS Nano</i> , 2010, 4, 4609-4620.	7.3	136
14	The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 197-205.	1.9	136
15	Fibrin(ogen) and thrombotic disease. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 294-305.	1.9	135
16	International Registry on Factor XIII Deficiency: A basis formed mostly on European data. <i>Thrombosis and Haemostasis</i> , 2007, 97, 914-921.	1.8	129
17	Subunit Antigen and Activity Levels of Blood Coagulation Factor XIII in Healthy Individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2012-2016.	1.1	128
18	The molecular physiology and pathology of fibrin structure/function. <i>Blood Reviews</i> , 2005, 19, 275-288.	2.8	126

#	ARTICLE	IF	CITATIONS
19	Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin Î±-chain crosslinking. <i>Blood</i> , 2015, 126, 1940-1948.	0.6	121
20	Functional Analysis of the Fibrinogen Á± Thr312Ala Polymorphism. <i>Circulation</i> , 2003, 107, 2326-2330.	1.6	120
21	Fibrinogen gamma-chain splice variant Î³â€² alters fibrin formation and structure. <i>Blood</i> , 2003, 102, 535-540.	0.6	119
22	Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 909-919.	1.9	116
23	Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. <i>Blood</i> , 2011, 118, 3942-3951.	0.6	114
24	Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. <i>Lancet, The</i> , 2002, 359, 667-671.	6.3	103
25	Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1054-1066.	1.9	102
26	Functional analysis of fibrin Î³-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. <i>Blood</i> , 2007, 110, 902-907.	0.6	101
27	Immobilized fibrinogen activates human platelets through glycoprotein VI. <i>Haematologica</i> , 2018, 103, 898-907.	1.7	101
28	Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 712-717.	1.1	97
29	The pleiotropic role of the fibrinogen Î³â€² chain in hemostasis. <i>Blood</i> , 2009, 114, 3994-4001.	0.6	91
30	The Effect of Dimethylbiguanide on Thrombin Activity, FXIII Activation, Fibrin Polymerization, and Fibrin Clot Formation. <i>Diabetes</i> , 2002, 51, 189-197.	0.3	90
31	A sequence variant associated with sortilin-1 (SORT1) on 1p13.3 is independently associated with abdominal aortic aneurysm. <i>Human Molecular Genetics</i> , 2013, 22, 2941-2947.	1.4	88
32	A fibrin biofilm covers blood clots and protects from microbial invasion. <i>Journal of Clinical Investigation</i> , 2018, 128, 3356-3368.	3.9	88
33	Î±~Î± Cross-Links Increase Fibrin Fiber Elasticity and Stiffness. <i>Biophysical Journal</i> , 2012, 102, 168-175.	0.2	85
34	Thrombus Structural Composition in Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2370-2383.	1.1	83
35	Clot properties and cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2014, 112, 901-908.	1.8	80
36	A Variant in <i>LDLR</i> Is Associated With Abdominal Aortic Aneurysm. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 498-504.	5.1	78

#	ARTICLE	IF	CITATIONS
37	Fibrin and D-dimer bind to monomeric GPVI. <i>Blood Advances</i> , 2017, 1, 1495-1504.	2.5	72
38	Mechanisms of thrombosis and cardiovascular complications in COVID-19. <i>Thrombosis Research</i> , 2021, 200, 1-8.	0.8	72
39	Common variation in the C-terminal region of the fibrinogen β^2 -chain: effects on fibrin structure, fibrinolysis and clot rigidity. <i>Blood</i> , 2008, 111, 643-650.	0.6	71
40	Roles of fibrin α^1 - and α^3 -chain specific cross-linking by FXIIIa in fibrin structure and function. <i>Thrombosis and Haemostasis</i> , 2014, 112, 842-850.	1.8	69
41	Role of Fibrin Structure in Thrombosis and Vascular Disease. <i>Advances in Protein Chemistry and Structural Biology</i> , 2011, 83, 75-127.	1.0	68
42	Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. <i>British Journal of Haematology</i> , 2002, 119, 169-175.	1.2	66
43	Fibrin clot structure in patients with end-stage renal disease. <i>Thrombosis and Haemostasis</i> , 2007, 98, 339-345.	1.8	66
44	Double diabetes: A distinct high-risk group?. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2609-2618.	2.2	65
45	A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2487-2496.	1.9	61
46	The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. <i>Blood</i> , 2000, 96, 988-95.	0.6	61
47	Genetics of fibrin clot structure: a twin study. <i>Blood</i> , 2004, 103, 1735-1740.	0.6	59
48	Evidence that fibrinogen β^2 directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1072-1080.	1.9	59
49	Alterations in Fibrin Structure in Patients with Liver Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 389-396.	1.5	59
50	Interactions between factor XIII and the α^1 C region of fibrinogen. <i>Blood</i> , 2011, 117, 3460-3468.	0.6	56
51	Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. <i>Diabetes Care</i> , 2000, 23, 703-705.	4.3	55
52	Clot Architecture Is Altered in Abdominal Aortic Aneurysms and Correlates With Aneurysm Size. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 3004-3010.	1.1	55
53	Thrombin and fibrinogen β^2 impact clot structure by marked effects on intrafibrillar structure and protofibril packing. <i>Blood</i> , 2016, 127, 487-495.	0.6	53
54	Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. <i>British Journal of Haematology</i> , 2001, 113, 537-543.	1.2	51

#	ARTICLE	IF	CITATIONS
55	Gender-Specific Alterations in Fibrin Structure Function in Type 2 Diabetes: Associations with Cardiometabolic and Vascular Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2282-E2287.	1.8	51
56	Markers of inflammation in men with small abdominal aortic aneurysm. <i>Journal of Vascular Surgery</i> , 2010, 52, 145-151.	0.6	49
57	Fibrinogen and Fibrin Clot Structure in Diabetes. <i>Herz</i> , 2004, 29, 470-9.	0.4	48
58	Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. <i>Blood</i> , 2003, 102, 25-30.	0.6	46
59	Raised Plasma Fibrinogen Concentration in Patients With Abdominal Aortic Aneurysm. <i>Angiology</i> , 2006, 57, 607-614.	0.8	45
60	Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 249-256.	0.8	41
61	Factor XIII: recommended terms and abbreviations1. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 181-183.	1.9	39
62	Roles of Low Specificity and Cofactor Interaction Sites on Thrombin during Factor XIII Activation. <i>Journal of Biological Chemistry</i> , 2003, 278, 32020-32026.	1.6	37
63	Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. <i>Journal of Vascular Surgery</i> , 2008, 48, 1497-1503.e1.	0.6	35
64	Evidence that fibrinogen β regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans. <i>Blood</i> , 2013, 121, 3254-3260.	0.6	35
65	The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. <i>Haematologica</i> , 2018, 103, 9-17.	1.7	35
66	Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen β . <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1669-1678.	1.9	33
67	The role of activated coagulation factor XII in overall clot stability and fibrinolysis. <i>Thrombosis Research</i> , 2015, 136, 474-480.	0.8	33
68	Does fibrin(ogen) bind to monomeric or dimeric GPVI, or not at all?. <i>Platelets</i> , 2019, 30, 281-289.	1.1	32
69	The activation peptide cleft exposed by thrombin cleavage of FXIII-A2 contains a recognition site for the fibrinogen β chain. <i>Blood</i> , 2013, 121, 2117-2126.	0.6	31
70	Elevated fibrinogen causes thrombosis. <i>Blood</i> , 2011, 117, 4687-4688.	0.6	28
71	The (Patho)physiology of Fibrinogen β . <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 344-355.	1.5	28
72	Joint Linkage and Association of Six Single-Nucleotide Polymorphisms in the Factor XIII-A Subunit Gene Point to V34L As the Main Functional Locus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1914-1919.	1.1	26

#	ARTICLE	IF	CITATIONS
73	Factor XIII Activity and Antigen Levels in Patients with Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2001, 85, 569-570.	1.8	25
74	Nanoscale Probing Reveals that Reduced Stiffness of Clots from Fibrinogen Lacking 42 N-Terminal B β -Chain Residues Is Due to the Formation of Abnormal Oligomers. <i>Biophysical Journal</i> , 2009, 96, 2415-2427.	0.2	25
75	Insights into the composition of stroke thrombi: heterogeneity and distinct clot areas impact treatment. <i>Haematologica</i> , 2020, 105, 257-259.	1.7	25
76	Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 618-626.	1.9	24
77	Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 308-316.	1.1	23
78	Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer. <i>Blood</i> , 2021, 137, 3443-3453.	0.6	23
79	The Role of Fibrin(ogen) in Wound Healing and Infection Control. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 174-187.	1.5	23
80	Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2192-2201.	1.9	22
81	Fibrin clot structure in patients with congenital dysfibrinogenaemia. <i>Thrombosis Research</i> , 2016, 137, 189-195.	0.8	22
82	Nonredundant Roles of Platelet Glycoprotein VI and Integrin α IIb β 3 in Fibrin-Mediated Microthrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e97-e111.	1.1	22
83	Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-aged men. <i>British Journal of Haematology</i> , 2002, 118, 825-832.	1.2	21
84	Plasma thrombin-antithrombin complex, prothrombin fragments 1 and 2, and D-dimer levels are elevated after endovascular but not open repair of infrarenal abdominal aortic aneurysm. <i>Journal of Vascular Surgery</i> , 2013, 57, 1512-1518.	0.6	21
85	Novel mechanisms that regulate clot structure/function. <i>Thrombosis Research</i> , 2016, 141, S25-S27.	0.8	21
86	Cardiovascular disease and heritability of the prothrombotic state. <i>Blood Reviews</i> , 2009, 23, 67-78.	2.8	20
87	Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction. <i>Blood</i> , 2011, 117, 6694-6701.	0.6	19
88	CVD risk factors are related to plasma fibrin clot properties independent of total and or β -fibrinogen concentration. <i>Thrombosis Research</i> , 2014, 134, 963-969.	0.8	19
89	GPVI (Glycoprotein VI) Interaction With Fibrinogen Is Mediated by Avidity and the Fibrinogen β -C-Region. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1092-1104.	1.1	19
90	A collaborative study to establish the 1st International Standard for factor XIII plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1923-1929.	1.9	17

#	ARTICLE	IF	CITATIONS
91	Alteration of fibrin clot properties by ultrafine particulate matter. <i>Thrombosis and Haemostasis</i> , 2010, 103, 103-113.	1.8	17
92	Fibrinogen Î³â€² increases the sensitivity to activated protein C in normal and factor V Leiden plasma. <i>Blood</i> , 2014, 124, 1531-1538.	0.6	17
93	Polyphosphate delays fibrin polymerisation and alters the mechanical properties of the fibrin network. <i>Thrombosis and Haemostasis</i> , 2016, 116, 897-903.	1.8	17
94	Fibrin clot structure is affected by levels of particulate air pollution exposure in patients with venous thrombosis. <i>Environment International</i> , 2016, 92-93, 70-76.	4.8	17
95	Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications. <i>Blood</i> , 2019, 133, 1233-1244.	0.6	17
96	A study of human coagulation factor XIII A-subunit by electrospray ionisation mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2000, 14, 1607-1611.	0.7	15
97	Fibrinogen Î±Câ€² regions are not directly involved in fibrin polymerization as evidenced by a â€œDoubleâ€•recombinant fibrinogen mutant and knobsâ€•mimic peptides. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 802-814.	1.9	15
98	Fibrinolysis in Acute and Chronic Cardiovascular Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 490-505.	1.5	15
99	Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 795-801.	1.9	14
100	Clot structure and fibrinolytic potential in patients with post thrombotic syndrome. <i>Thrombosis Research</i> , 2016, 137, 85-91.	0.8	14
101	The Relation Between Insulin Resistance and Hemostasis: Pleiotropic Genes and Common Environment. <i>Twin Research and Human Genetics</i> , 2003, 6, 152-161.	1.3	14
102	Ranking reactive glutamines in the fibrinogen Î±C region that are targeted by blood coagulant factor XIII. <i>Blood</i> , 2016, 127, 2241-2248.	0.6	13
103	Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a). <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1834-1844.	1.9	13
104	Fibrinogen splice variation and cross-linking: Effects on fibrin structure/function and role of fibrinogen Î³â€² as thrombomodulin II. <i>Matrix Biology</i> , 2017, 60-61, 8-15.	1.5	13
105	Fibrinogen Î±C-subregions critically contribute blood clot fibre growth, mechanical stability, and resistance to fibrinolysis. <i>ELife</i> , 2021, 10, .	2.8	13
106	Coagulation Factor XIII-A Subunit Missense Mutation in the Pathobiology of Autosomal Dominant Multiple Dermatofibromas. <i>Journal of Investigative Dermatology</i> , 2020, 140, 624-635.e7.	0.3	12
107	Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1269-1281.	1.0	12
108	Regarding â€œAltered fibrin clot structure and function in individuals with intermittent claudicationâ€•. <i>Journal of Vascular Surgery</i> , 2009, 49, 1088-1089.	0.6	11

#	ARTICLE	IF	CITATIONS
109	Partial deletion of the Î±C-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1135-1144.	1.8	11
110	Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. <i>Thrombosis and Haemostasis</i> , 1999, 81, 203-7.	1.8	11
111	Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris. <i>American Journal of Cardiology</i> , 2000, 85, 527-531.	0.7	10
112	The alpha-2-antiplasmin Arg407Lys polymorphism is associated with Abdominal Aortic Aneurysm. <i>Thrombosis Research</i> , 2014, 134, 723-728.	0.8	10
113	Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A. <i>FEBS Journal</i> , 2020, 287, 452-464.	2.2	10
114	Elimination of fibrin Î³-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2103226118.	3.3	10
115	A new red cell shape helps the clot. <i>Blood</i> , 2014, 123, 1442-1443.	0.6	9
116	Effects of riboflavin and amotosalen photoactivation systems for pathogen inactivation of freshâ€frozen plasma on fibrin clot structure. <i>Transfusion</i> , 2016, 56, 41-48.	0.8	9
117	High fibrinogen Î³â€² levels in patient plasma increase clot formation at arterial and venous shear. <i>Blood Advances</i> , 2021, 5, 3468-3477.	2.5	9
118	Automated Fiber Diameter and Porosity Measurements of Plasma Clots in Scanning Electron Microscopy Images. <i>Biomolecules</i> , 2021, 11, 1536.	1.8	9
119	Vascular Dementia and Crosstalk Between the Complement and Coagulation Systems. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 803169.	1.1	9
120	Clot Structure and Fibrinolysis in Thrombosis and Hemostasis. <i>BioMed Research International</i> , 2017, 2017, 1-2.	0.9	8
121	Impaired factor XIII activation in patients with congenital afibrinogenemia. <i>Haematologica</i> , 2019, 104, e111-e113.	1.7	8
122	Quantitative analysis of clot density, fibrin fiber radius, and protofibril packing in acute phase myocardial infarction. <i>Thrombosis Research</i> , 2021, 205, 110-119.	0.8	8
123	Relationship of coagulation and fibrinolytic variables with arterial structure and function in Africans. <i>Thrombosis Research</i> , 2014, 134, 78-83.	0.8	7
124	The role of Î²-barrels 1 and 2 in the enzymatic activity of factor XIII A-subunit. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1391-1401.	1.9	6
125	Urban Particulate Matter Induces Changes in Gene Expression in Vascular Endothelial Cells that Are Associated with Altered Clot Structure In Vitro. <i>Thrombosis and Haemostasis</i> , 2018, 118, 266-278.	1.8	6
126	On the localization of the cleavage site in human alphaâ€²â€²-antiplasmin, involved in the generation of the nonâ€plasinogen binding form. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1162-1170.	1.9	6

#	ARTICLE	IF	CITATIONS
127	Assessment and determinants of whole blood and plasma fibrinolysis in patients with mild bleeding symptoms. <i>Thrombosis Research</i> , 2019, 174, 88-94.	0.8	5
128	Contribution of Red Blood Cells and Clot Structure to Thrombosis. <i>Blood</i> , 2015, 126, SCI-15-SCI-15.	0.6	5
129	The quest for the Holy Grail of tissue factor pathway inhibitor deficiency has just begun. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 649-650.	1.9	4
130	Denser matters. <i>Blood</i> , 2009, 114, 3978-3979.	0.6	4
131	Inhibition of plasmin-mediated TAFI activation may affect development but not progression of abdominal aortic aneurysms. <i>PLoS ONE</i> , 2017, 12, e0177117.	1.1	4
132	A Comparative Assessment Study of Known Small-molecule GPVI Modulators. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 171-181.	1.3	4
133	Fibrin protofibril packing and clot stability are enhanced by extended knob-hole interactions and catch-slip bonds. <i>Blood Advances</i> , 2022, , .	2.5	4
134	Novel interaction of properdin and coagulation factor XI: Crosstalk between complement and coagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12715.	1.0	4
135	Common FXIII and Fibrinogen Polymorphisms in Abdominal Aortic Aneurysms. <i>PLoS ONE</i> , 2014, 9, e112407.	1.1	3
136	BÎ²Arg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes. <i>Thrombosis and Haemostasis</i> , 2017, 117, 295-302.	1.8	3
137	The ₉₅RGD₉₇ sequence on the Aα chain of fibrinogen is essential for binding to its erythrocyte receptor. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 1985-1992.	3.3	3
138	Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. <i>American Journal of Hematology</i> , 2020, 95, 944-952.	2.0	3
139	High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1020-3.	1.8	3
140	Getting to grips with complexity of disease will make genomics useful in arterial thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 450-453.	1.9	1
141	Changes to the structure of blood clots formed in the presence of fine particulate matter. <i>Journal of Physics: Conference Series</i> , 2009, 151, 012029.	0.3	1
142	Allele-specific alternative splicing; the tail of FXIII-B tells its own tale. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1081-1083.	1.9	0
143	Counting 1 fibrin molecule at a time. <i>Blood</i> , 2013, 121, 1251-1252.	0.6	0
144	Thrombosis and Hemostasis--First North Sea Conference. 12-17 June 2000, Maastricht, The Netherlands. <i>IDrugs: the Investigational Drugs Journal</i> , 2000, 3, 1158-61.	0.7	0